Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Change in Acquisitions & Divestments (2022 - 2025)

Historic Change in Acquisitions & Divestments for Corvus Pharmaceuticals (CRVS) over the last 4 years, with Q3 2025 value amounting to $28.5 million.

  • Corvus Pharmaceuticals' Change in Acquisitions & Divestments rose 9089.39% to $28.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $74.1 million, marking a year-over-year increase of 9773.12%. This contributed to the annual value of $42.6 million for FY2024, which is 3192.6% down from last year.
  • According to the latest figures from Q3 2025, Corvus Pharmaceuticals' Change in Acquisitions & Divestments is $28.5 million, which was up 9089.39% from $19.3 million recorded in Q2 2025.
  • Corvus Pharmaceuticals' 5-year Change in Acquisitions & Divestments high stood at $28.5 million for Q3 2025, and its period low was $810000.0 during Q1 2022.
  • Its 4-year average for Change in Acquisitions & Divestments is $13.9 million, with a median of $14.9 million in 2024.
  • Its Change in Acquisitions & Divestments has fluctuated over the past 5 years, first soared by 208827.16% in 2023, then tumbled by 7392.95% in 2024.
  • Over the past 4 years, Corvus Pharmaceuticals' Change in Acquisitions & Divestments (Quarter) stood at $15.4 million in 2022, then crashed by 40.85% to $9.1 million in 2023, then skyrocketed by 56.73% to $14.3 million in 2024, then surged by 99.89% to $28.5 million in 2025.
  • Its last three reported values are $28.5 million in Q3 2025, $19.3 million for Q2 2025, and $12.0 million during Q1 2025.